Patau Syndrome (Trisomy 13)

Overview

Plain-Language Overview

Patau Syndrome (Trisomy 13) is a rare genetic disorder caused by having an extra copy of chromosome 13. This condition affects many parts of the body, especially the brain, heart, and facial structures. Babies with this syndrome often have serious health problems such as cleft lip or palate, extra fingers or toes, and severe developmental delays. The extra chromosome disrupts normal growth and development, leading to life-threatening complications. Most infants with Patau Syndrome have a very short life expectancy due to these severe abnormalities.

Clinical Definition

Patau Syndrome (Trisomy 13) is a chromosomal disorder characterized by the presence of a full or partial extra copy of chromosome 13 in all or some cells, resulting in trisomy 13. This aneuploidy arises primarily from nondisjunction during meiosis, leading to multiple congenital anomalies affecting the central nervous system, cardiovascular system, and craniofacial development. Key clinical features include holoprosencephaly, polydactyly, microphthalmia, and congenital heart defects such as ventricular septal defects. The syndrome is associated with profound intellectual disability and high neonatal mortality. Diagnosis is critical for prognosis and genetic counseling.

Inciting Event

Meiotic nondisjunction during gametogenesis leads to an extra chromosome 13 in the zygote.
Postzygotic mitotic errors can cause mosaic trisomy 13, resulting in variable phenotypic severity.

Latency Period

Symptoms and congenital anomalies are present at birth due to prenatal developmental defects.
Prenatal diagnosis is possible by second trimester via ultrasound and genetic testing.

Diagnostic Delay

Diagnosis may be delayed due to overlapping features with other trisomies or syndromes.
Mild or mosaic cases can present with subtle anomalies leading to initial misdiagnosis.
Lack of prenatal screening or limited access to genetic testing can postpone diagnosis.

Clinical Presentation

Signs & Symptoms

Severe intellectual disability and developmental delay
Feeding difficulties due to cleft palate and hypotonia
Seizures and abnormal muscle tone
Respiratory distress from central nervous system malformations
Failure to thrive in the neonatal period

History of Present Illness

Newborns present with multiple congenital anomalies including microcephaly, cleft lip/palate, and polydactyly.
Severe feeding difficulties and respiratory distress are common due to craniofacial and neurological defects.
Early onset of seizures and hypotonia reflect central nervous system involvement.
Congenital heart defects cause signs of heart failure or cyanosis in the neonatal period.

Past Medical History

There is typically no relevant past medical history in the neonate due to the congenital nature of the syndrome.
Maternal history may include advanced age or previous pregnancies affected by chromosomal abnormalities.
No prior medical interventions are usually present before diagnosis.

Family History

Most cases are sporadic with no family history of trisomy 13.
A family history of balanced translocations involving chromosome 13 increases recurrence risk.
Rarely, familial cases with mosaicism or inherited chromosomal rearrangements are reported.

Physical Exam Findings

Holoprosencephaly with midline facial defects such as cleft lip and palate
Microphthalmia or anophthalmia with polydactyly (extra fingers or toes)
Rocker-bottom feet and low-set ears
Scalp defects (cutis aplasia) and microcephaly
Congenital heart defects such as ventricular septal defect or patent ductus arteriosus

Diagnostic Workup

Diagnostic Criteria

Diagnosis of Patau Syndrome is established by identifying the characteristic clinical features such as holoprosencephaly, polydactyly, and midline facial defects. Confirmation requires karyotype analysis demonstrating trisomy of chromosome 13 in peripheral blood or other tissues. Prenatal diagnosis can be performed via chorionic villus sampling or amniocentesis with chromosomal analysis. Additional supportive findings include abnormal ultrasound findings and elevated maternal serum markers. Genetic testing remains the gold standard for definitive diagnosis.

Pathophysiology

Key Mechanisms

Trisomy 13 results from the presence of an extra copy of chromosome 13 in all or some cells, causing widespread gene dosage imbalance.
Disrupted expression of multiple genes on chromosome 13 leads to abnormal embryonic development affecting the central nervous system, heart, and midline facial structures.
Defective neuronal proliferation and migration contribute to severe central nervous system malformations such as holoprosencephaly.
Impaired development of the cardiovascular system results in congenital heart defects like ventricular septal defects and patent ductus arteriosus.
Abnormalities in craniofacial morphogenesis cause characteristic facial features including cleft lip/palate and microphthalmia.

Involvement	Details
Organs	Brain exhibits holoprosencephaly and other severe malformations causing profound neurodevelopmental delay.
	Heart frequently has structural defects such as ventricular septal defects and patent ductus arteriosus.
	Kidneys may have cystic dysplasia contributing to renal dysfunction.
Tissues	Craniofacial mesenchyme is abnormally developed, resulting in cleft lip, cleft palate, and microphthalmia.
	Cardiac tissue is malformed, causing congenital heart defects that contribute to morbidity.
	Neural tissue shows incomplete forebrain division leading to severe neurological impairment.
Cells	Neural crest cells contribute to craniofacial and cardiac malformations characteristic of Patau syndrome.
	Cardiomyocytes are affected by structural heart defects such as ventricular septal defects and atrial septal defects.
	Epithelial cells in the brain show abnormal development leading to holoprosencephaly.
Chemical Mediators	Sonic hedgehog (SHH) signaling disruption is implicated in midline defects including holoprosencephaly seen in Patau syndrome.

Treatments

Pharmacological Treatments

Non-pharmacological Treatments

Provide comprehensive supportive care including respiratory support and nutritional management to address multisystem involvement.
Offer surgical correction for treatable congenital anomalies such as cleft lip and polydactyly when feasible.
Implement early intervention programs with physical and occupational therapy to optimize developmental outcomes.
Provide genetic counseling to families regarding prognosis and recurrence risk.

Prevention

Pharmacological Prevention

There are no medication-based prophylaxis options to prevent trisomy 13
Prenatal folic acid supplementation reduces neural tube defects but not trisomy 13
No pharmacological agents can prevent meiotic nondisjunction causing trisomy 13

Non-pharmacological Prevention

Prenatal genetic counseling for at-risk couples
Prenatal screening with noninvasive prenatal testing (NIPT) and diagnostic amniocentesis
Advanced maternal age counseling due to increased risk of trisomy 13
Preimplantation genetic diagnosis during IVF for families with known risk
Early ultrasound screening to detect fetal anomalies suggestive of trisomy 13

Outcome & Complications

Complications

Respiratory failure due to central apnea and brainstem dysfunction
Recurrent infections from poor feeding and aspiration
Seizure disorders leading to neurological deterioration
Congestive heart failure from structural cardiac defects
Early neonatal death due to multisystem organ involvement

Short-term Sequelae	Long-term Sequelae
Neonatal respiratory distress requiring ventilatory support Feeding intolerance necessitating tube feeding Seizure management challenges in the neonatal period Hypotonia causing poor motor function Frequent hospitalizations for infections and cardiac issues	Profound intellectual disability with no independent function Severe growth failure and failure to thrive Chronic respiratory insufficiency Persistent seizures refractory to treatment Early mortality with most infants not surviving beyond the first year

Differential Diagnoses

Patau Syndrome (Trisomy 13) versus Edwards Syndrome (Trisomy 18)

Patau Syndrome (Trisomy 13)	Edwards Syndrome (Trisomy 18)
Polydactyly and midline facial defects such as cleft lip/palate	Clenched fists with overlapping fingers and prominent occiput
Holoprosencephaly-associated cardiac anomalies including atrial septal defects	Ventricular septal defects and patent ductus arteriosus are common
High neonatal mortality with most infants dying within the first month	Most infants survive beyond the neonatal period but rarely past the first year

Patau Syndrome (Trisomy 13) versus Holoprosencephaly (non-chromosomal causes)

Patau Syndrome (Trisomy 13)	Holoprosencephaly (non-chromosomal causes)
Chromosomal trisomy 13 causing holoprosencephaly	Sporadic or teratogenic causes such as maternal diabetes or alcohol use
Midline facial defects with polydactyly and other systemic anomalies	Midline facial defects without polydactyly
Trisomy 13 detected by karyotype or chromosomal microarray	Normal karyotype or single gene mutations

Patau Syndrome (Trisomy 13) versus Cri-du-chat Syndrome

Patau Syndrome (Trisomy 13)	Cri-du-chat Syndrome
Trisomy of chromosome 13	Deletion of the short arm of chromosome 5 (5p-)
No characteristic cry; multiple congenital anomalies predominate	High-pitched, cat-like cry in infancy
Microcephaly with midline defects and cleft lip/palate	Microcephaly with round face and hypertelorism

Patau Syndrome (Trisomy 13) versus Smith-Lemli-Opitz Syndrome

Patau Syndrome (Trisomy 13)	Smith-Lemli-Opitz Syndrome
Chromosomal trisomy without primary metabolic defect	Deficiency of 7-dehydrocholesterol reductase causing low cholesterol
Polydactyly and midline facial clefts	Microcephaly, ptosis, syndactyly of 2nd and 3rd toes
Trisomy 13 detected by karyotype	Elevated 7-dehydrocholesterol levels in plasma